Théodora Bejan‐Angoulvant
About
Théodora Bejan‐Angoulvant is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine.
According to data from OpenAlex, Théodora Bejan‐Angoulvant has authored 63 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 14 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Théodora Bejan‐Angoulvant's work include Blood Pressure and Hypertension Studies (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Théodora Bejan‐Angoulvant is often cited by papers focused on Blood Pressure and Hypertension Studies (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Théodora Bejan‐Angoulvant collaborates with scholars based in France, Switzerland and Belgium. Théodora Bejan‐Angoulvant's co-authors include Rémy Boussageon, Behrouz Kassaï, Mitra Saadatian‐Elahi, Sylvie Erpeldinger, François Gueyffier, Catherine Cornu, J. Michael Wright, Denis Angoulvant, Gilles Paintaud and David Ternant and has published in prestigious journals such as PLoS ONE, Scientific Reports and CHEST Journal.
In The Last Decade
Théodora Bejan‐Angoulvant
60 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Théodora Bejan‐Angoulvant France | 20 | 619 | 395 | 325 | 242 | 238 | 63 | 1.8k | ||
| Wanjie Sun United States | 21 | 837 1.4× | 218 0.6× | 273 0.8× | 149 0.6× | 248 1.0× | 40 | 1.9k | ||
| Ole Torffvit Sweden | 30 | 584 0.9× | 332 0.8× | 318 1.0× | 223 0.9× | 235 1.0× | 96 | 2.1k | ||
| Søren Tang Knudsen Denmark | 21 | 415 0.7× | 478 1.2× | 208 0.6× | 228 0.9× | 163 0.7× | 63 | 1.4k | ||
| Mogher Khamaisi Israel | 22 | 305 0.5× | 212 0.5× | 372 1.1× | 157 0.6× | 204 0.9× | 52 | 2.0k | ||
| Mari-Anne Gall Denmark | 17 | 797 1.3× | 725 1.8× | 253 0.8× | 74 0.3× | 304 1.3× | 26 | 2.1k | ||
| Allan Kofoed‐Enevoldsen Denmark | 20 | 962 1.6× | 914 2.3× | 280 0.9× | 172 0.7× | 362 1.5× | 49 | 2.6k | ||
| Kustaa Hietala Finland | 17 | 617 1.0× | 210 0.5× | 134 0.4× | 177 0.7× | 183 0.8× | 26 | 1.2k | ||
| Richard E. Gilbert Australia | 24 | 839 1.4× | 681 1.7× | 579 1.8× | 68 0.3× | 289 1.2× | 44 | 2.2k | ||
| H.-H. Parving Denmark | 18 | 989 1.6× | 769 1.9× | 231 0.7× | 92 0.4× | 230 1.0× | 30 | 2.1k | ||
| Jørgen Jeppesen Denmark | 15 | 897 1.4× | 497 1.3× | 246 0.8× | 80 0.3× | 514 2.2× | 22 | 1.8k |
Countries citing papers authored by Théodora Bejan‐Angoulvant
Since
Specialization
Citations
This map shows the geographic impact of Théodora Bejan‐Angoulvant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Théodora Bejan‐Angoulvant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Théodora Bejan‐Angoulvant more than expected).
Fields of papers citing papers by Théodora Bejan‐Angoulvant
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Théodora Bejan‐Angoulvant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Théodora Bejan‐Angoulvant. The network helps show where Théodora Bejan‐Angoulvant may publish in the future.
Co-authorship network of co-authors of Théodora Bejan‐Angoulvant
This figure shows the co-authorship network connecting the top 25 collaborators of Théodora Bejan‐Angoulvant. A scholar is included among the top collaborators of Théodora Bejan‐Angoulvant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Théodora Bejan‐Angoulvant. Théodora Bejan‐Angoulvant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bejan‐Angoulvant, Théodora, Julien Ternacle, Étienne Puymirat, et al.. (2025). Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis. JACC Heart Failure. 13(8). 102492–102492.
2.
Pathak, Atul, Romain Boulestreau, Pierre Lantelme, et al.. (2024). Catheter-based renal denervation in the treatment of arterial hypertension: An expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French Society of Thoracic and Cardiovascular Surgery (SFCTCV) and French Society of Vascular and Endovascular Surgery (SCVE). Archives of cardiovascular diseases. 117(10). 601–611.
3.
Bejan‐Angoulvant, Théodora, et al.. (2024). Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis. Current Hypertension Reports. 26(11). 419–429.
4.
Marcelli, Christian, et al.. (2024). Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol. BMJ Open. 14(9). e087872–e087872.
5.
Bouleti, Claire, Benjamin Alos, Alexis Jacquier, et al.. (2024). Rationale and design of the French cohort of acute myocarditis diagnosed by cardiac magnetic resonance imaging (MyocarditIRM). Archives of cardiovascular diseases. 117(6-7). 433–440.
6.
Ferreira, Marion, Théodora Bejan‐Angoulvant, S. Marchand‐Adam, et al.. (2024). Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial. Respiratory Medicine and Research. 87. 101144–101144.
7.
Bejan‐Angoulvant, Théodora, Jean‐Marc Naccache, Agnès Caille, et al.. (2020). Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial. Respiratory Medicine and Research. 78. 100770–100770.
8.
Dolladille, Charles, Théodora Bejan‐Angoulvant, Khalil Zaman, et al.. (2020). Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Archives of cardiovascular diseases. 113(6-7). 420–432.
9.
Lanznaster, Débora, Théodora Bejan‐Angoulvant, Jorge Gandía, Hélène Blasco, & Philippe Corcia. (2020). Is There a Role for Vitamin D in Amyotrophic Lateral Sclerosis? A Systematic Review and Meta-Analysis. Frontiers in Neurology. 11. 697–697.
10.
Bejan‐Angoulvant, Théodora & Joachim Alexandre. (2019). Mécanismes d’action et toxicités potentielles des anticorps monoclonaux. médecine/sciences. 35(12). 1114–1120.
11.
Thulliez, Marie, Denis Angoulvant, Pierre‐Jean Pisella, & Théodora Bejan‐Angoulvant. (2018). Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmology. 136(5). 557–557.
12.
Bejan‐Angoulvant, Théodora, et al.. (2018). A novel way to manage trastuzumab cardiotoxicity. Cancer Chemotherapy and Pharmacology. 81(4). 791–796.
13.
Lioger, Bertrand, F. Maillot, David Ternant, et al.. (2018). Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials. The Journal of Pediatrics. 204. 225–233.e8.
14.
Ferreira, Marion, Éric Pichon, D. Carmier, et al.. (2018). Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. Targeted Oncology. 13(4). 509–515.
15.
Bejan‐Angoulvant, Théodora, et al.. (2018). A systematic review of the learning curve in robotic surgery: range and heterogeneity. Surgical Endoscopy. 33(2). 353–365.
16.
Bejan‐Angoulvant, Théodora, Catherine Cornu, Philippe S. Archambault, et al.. (2015). Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes & Metabolism. 41(3). 195–201.
17.
Angoulvant, Denis, Théodora Bejan‐Angoulvant, Fabrice Ivanés, et al.. (2015). Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. CHEST Journal. 148(2). 491–498.
18.
Angoulvant, Denis, et al.. (2014). Ischaemic postconditioning reduces infarct size: Systematic review and meta-analysis of randomized controlled trials. Archives of cardiovascular diseases. 108(1). 39–49.
19.
Bejan‐Angoulvant, Théodora, Cyrille Bergerot, Laurent Juillard, et al.. (2012). Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study. Nephrology Dialysis Transplantation. 27(7). 2886–2891.
20.
Marchant, Ivanny, Patrice Nony, Michel Cucherat, et al.. (2011). The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies. PLoS ONE. 6(3). e17508–e17508.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wanjie Sun Breakdown of academic impact, for papers by Ole Torffvit Breakdown of academic impact, for papers by Søren Tang Knudsen Breakdown of academic impact, for papers by Mogher Khamaisi Breakdown of academic impact, for papers by Mari-Anne Gall Breakdown of academic impact, for papers by Allan Kofoed‐Enevoldsen Breakdown of academic impact, for papers by Kustaa Hietala Breakdown of academic impact, for papers by Richard E. Gilbert Breakdown of academic impact, for papers by H.-H. Parving Breakdown of academic impact, for papers by Jørgen Jeppesen